91550-08-2

Usage

Uses

Used in Pharmaceutical Research:
(S)-1-Boc-2-acetyl-pyrrolidine is used as a chiral building block for the synthesis of pharmaceutical intermediates, due to its unique chiral center and versatile reactivity in organic synthesis.
Used in Medicinal Chemistry:
(S)-1-Boc-2-acetyl-pyrrolidine is employed as a key component in the development of new drugs, leveraging its potential pharmacological properties and biological activities to create novel therapeutic agents.
Used in Organic Synthesis:
(S)-1-Boc-2-acetyl-pyrrolidine is utilized as a versatile intermediate in organic synthesis, contributing to the creation of a wide range of chemical compounds for various applications.

Upstream product

• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 676-58-4 methylmagnesium chloride 
• 33857-76-0 Boc-proline 2-thiopyridyl ester 
• 239483-01-3 (S)-2-(methoxymethylcarbamoyl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 115186-37-3 tert-butyl (2S)-2-{[N-methoxy(N-methyl)amino]carbonyl}pyrrolidine-1-carboxylate 
• 147-85-3 L-proline 
• 917-54-4 methyllithium 
• 23356-96-9 (S)-1-Pyrrolidin-2-yl-methanol 
• 69610-41-9 Boc-L-Pro-H 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 24424-99-5 di-tert-butyl dicarbonate 
• 75-16-1 methylmagnesium bromide 
• 290327-92-3 tert-butyl-(2S)-2-(1-hydroxyethyl)pyrrolidine-1-carboxylate 
• 141874-26-2 N-Boc-(S)-proline chloride 

Downstream Products

• 120966-82-7 L(-)-proline 
• 1071976-38-9 (S)-tert-butyl 2-(4-phenyl-1,2,3-thiadiazol-5-ylcarbamoyl)pyrrolidine-1-carboxylate 
• 1254223-92-1 tert-butyl-2-(1-(2-tosylhydrazineylidene)ethyl)pyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

Macrocyclic compound serving as ALK and ROS regulators

The invention belongs to the field of medicinal chemistry, and relates to a macrocyclic compound serving as an ALK and ROS regulators, in particular to a compound as shown in a formula I or pharmaceutically acceptable salt thereof, a preparation method, a

COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS

The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides reagents and methods for chirally controlled preparation of oligonucleotides. In some embodiments, technologies of the present disclosure are particularly useful for constructing challenging internucleotidic linkages, providing high yields and stereoselectivity.

Studies on Pumiliotoxin A Alkaloids: An Approach to Preparing the Indolizidinic Core by Intramolecular Diastereoselective N-Heterocyclic Carbene Catalyzed Benzoin Reaction

In this article, we describe the development of a convergent organocatalytic strategy to prepare the indolizidinic core of the pumiliotoxin A alkaloid family. The key step of the proposed strategy is based on a diastereoselective N-heterocyclic carbene ca

Rh2(II)-catalyzed selective aminomethylene migration from styryl azides

Rh2(II)-Carboxylate complexes were discovered to promote the selective migration of aminomethylenes in β,β-disubstituted styryl azides to form 2,3-disubstituted indoles. Mechanistic data are also presented that suggest that the migration occurs stepwise before diffusion of the iminium ion.

An intramolecular Tsuji-Trost reaction based approach to the synthesis of 6-methylene indolizidines

Herein we describe the efficient stereoselective preparation of C8 substituted indolizidines bearing a 6-methylene group, from the chiral pool starting material l-proline. This synthesis, employing a Tsuji-Trost reaction as the key step, represents a potentially, efficient route to pumiliotoxin natural product epimers. Crown Copyright

Arylation of α-chiral ketones by palladium-catalyzed cross-coupling reactions of tosylhydrazones with aryl halides

(Figure Presented) Papa was a rollin' ketone: Arylation of ketones with preservation of the chirality in configurationally unstable α-chiral ketones has been achieved by the palladium-catalyzed cross-coupling reaction between tosylhydrazones and aryl halides (see scheme; Boc=tert-butoxycarbonyl, Ts=4-toluenesulfonyl). The regioselectivity in the β-hydride elimination step is key for the retention of configuration.

BETA-SECRETASE INHIBITING COMPOUNDS HAVING OXO-DIHYDRO-PYRAZOLE MOIETY

Disclosed are compounds represented by Formula (I) as defined in the specification, or pharmaceutically acceptable salts or isomers thereof, and a pharmaceutical composition for inhibiting beta-secretase activity comprising a therapeutically effective amo

PROLINE BIS-AMIDE OREXIN RECEPTOR ANTAGONISTS

The present invention is directed to proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

Ketopyrrolidines and ketoazetidines as potent dipeptidyl peptidase IV (DPP IV) inhibitors

In this paper the synthesis and structure-activity relationships of two classes of electrophile-based DPP IV inhibitors, the ketopyrrolidines and ketoazetidines, is discussed. The in vitro potency, stability and ex vivo experiments were performed on select compounds within these series to determine their inhibitory capacity in plasma. In this paper, the synthesis and structure-activity relationships (SAR) of two classes of electrophile-based dipeptidyl peptidase IV (DPP IV) inhibitors, the ketopyrrolidines and ketoazetidines, is discussed. The SAR of these series demonstrate that the 2-thiazole, 2-benzothiazole, and 2-pyridylketones are optimal S1′ binding groups for potency against DPP IV. In addition, both cyclohexyl glycine (CHG) and octahydroindole carboxylate (OIC) serve as the most potent S2 binding groups within each series. Stereochemistry at the α-position of the central ring is relevant to potency within the ketopyrrolidines series, but not in the ketoazetidine series. Finally, the ketoazetidines display enhanced stability over the corresponding ketopyrrolidines, while maintaining their potency. In fact, certain stabilized ketoazetidines can maintain their in vitro potency and inhibit DPP IV in the plasma for up to 6 h.

4-Phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl-L-prolyl-2(S)-acylpyrrolidines as prolyl oligopeptidase inhibitors

New 4-phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl-L-prolyl-2(S)-acylpyrrolidines were synthesized. Their inhibitory activity against prolyl oligopeptidase from pig brain was tested in vitro. In the series of 4-phenylbutanoyl-2(S)-acylpyrrolidines, the cyclopentanecarbonyl and benzoyl derivatives were the best inhibitors having IC50 values of 30 and 23 nM, respectively. This series of compounds shows that the P1 pyrrolidine ring, which is common in most POP inhibitors, can be replaced by either a cyclopentyl ring or a phenyl ring, causing only a slight decrease in the inhibitory activity. In the series of 4-phenylbutanoyl-L-prolyl-2(S)-acylpyrrolidines the cyclopentanecarbonyl and benzoyl derivatives were not as active as in the series of 4-phenylbutanoyl-2(S)-acylpyrrolidines. The hydroxyacetyl derivative did however show high inhibitory activity. This compound is structurally similar to JTP-4819, which is one of the most potent prolyl oligopeptidase inhibitors. The acyl group in the two series of new compounds seems to bind to different sites of the enzyme, since the second series of new compounds did not show the same cyclopentanecarbonyl or benzoyl specificity as the first series.